The U.S. Food and Drug Administration (FDA) has approved a second indication for SKYRIZI® (risankizumab-rzaa) to treat adults with active psoriatic arthritis.
The European Commission has approved SKYRIZI® for the treatment of active psoriatic arthritis in adults.
Stay informed Join the email list to receive the latest information on psoriasis meetings, manuscripts and research. SUBSCRIBE now available COVID-19 Psoriasis Resource Center Information from around the world on psoriasis and coronavirus to assist dermatologists and the patients they serve explore now IPC STATEMENT on SARS-CoV-2 Vaccines and Psoriasis Six key take-aways that physicians and other healthcare practitioners should consider when administering the SARS-CoV-2 vaccine to psoriasis patients. READ FULL STATEMENT
Information from around the world on psoriasis and coronavirus to assist dermatologists and the patients they serve
Six key take-aways that physicians and other healthcare practitioners should consider when administering the SARS-CoV-2 vaccine to psoriasis patients.
READ FULL STATEMENT